Investigating the association of chemokine receptor 5 (CCR5) polymorphism with cervical cancer in human papillomavirus (HPV) positive patients

Acta Scientiarum - Health Sciences

Volumn 30, Issue 2, 2008, Pages 95-100

  Suzuki, Patrícia Sayuri ^a   de Oliveira, Karen Brajão ^a   Aoki, Mateus Nóbrega ^a   Tatakihara, Vera Lúcia Hideko ^a   Borelli, Sueli Donizete ^b   Watanabe, Maria Angelica Ehara ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

CCR5; Cervical cancer; HPV

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADOLESCENT; ADULT; AGED; ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVIX CANCER; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 59849117366     PISSN: 16799291     EISSN: 18078648     Source Type: Journal    
DOI: 10.4025/actascihealthsci.v30i2.944     Document Type: Article

References (42)

1. AZENSHTEIN, E. et al. The CC chemokine Rantes in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res., Baltimore, v. 62, n.4, p. 1093-1102, 2002.
2. BAGGIOLINI, M. Chemokines and leukocyte traffic. Nature, New York, v. 392, n. 6676, p. 565-568, 1998.
3. BALISTRERI, C.R. et al. CCR5 receptor: biologic and genetic implications in age-related diseases. Ann. N.Y. Acad. Sci., New York, v. 1100, p. 162-172, 2007.
4. BOSCH, F.X. et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. Bethesda, v. 87, n. 11, p. 796-802, 1995.
5. DEGERLI, N. et al. The D32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin. Biochem., Quebec, v. 38, n. 3, p.248-252, 2005.
6. DEWIN, D.R. et al. Identification and characterization of U83A viral chemokine, a broad and potent b chemokine agonist for human CCR's with unique selectivity and inhibition by spliced isoform. J. Immunol., Baltimore, v. 176, n. 1, p. 544-556, 2005.
7. DUELL, E.J. et al. Holly inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev., Philadelphia. v. 15, n. 4, p. 726-731, 2006.
8. ELUF-NETO, J. et al.. Human papillomavirus and invasive cervical cancer in Brazil. Br. J. Cancer, London, v. 69, n. 1, p. 114-119, 1994.
9. EVANS, E.M. et al. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res., Baltimore, v. 57, n. 14, p. 2943-2950, 1997.
10. FUJII, A. et al. Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int. J. Oncol., Athens, v. 24, n. 3, p. 529-538, 2004.
11. GHADERI, M. et al. Tumor necrosis factor a-11 and DRI5-DQ6 (B*0602) haplotype increases the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositve women in Northern Sweden. Cancer Epidemiol. Biomarkers Prev., Philadelphia, v. 9, n. 10, p. 1067-1070, 2000.
12. KAIMEN-MACIEL, D.R. et al. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int. J. Mol. Med., Athens, v. 20, n. 3, p. 337-344, 2007.
13. KHADEMI, B. et al. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol. Oncol. Res., Budapest, v. 14, n. 1, p. 45-50, 2008.
14. KLEINE-LOWINSKI, K. et al. Monocyte-chemoattractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int. J. Cancer, New York, v. 82, n. 1, p. 6-11, 1999.
15. KOSS, L.G.; DURFEE, G.R. Unusual patterns of squamous epithelium of the uterine cervix?: Cytological and pathologic study of koilocytotic atypia. Ann. N.Y. Acad. Sci., New York, v. 63, n. 6, p. 1245-1261, 1956.
16. LOETSCHER, P. et al. CCR5 is characteristic of Th1 lymphocytes. Nature, New York, v. 391, n. 6665, p. 344-345, 1998.
17. LUBOSHITS, G. et al. Elevated expression of the CC chemokines regulated on activation, normal T cell expressed and secreted (Rantes) in advanced breast carcinoma. Cancer Res., Baltimore, v. 59, n. 18, p. 4681-4687, 1999.
18. MEISELS, A.; FORTIN, R. Condylomatous lesions of the cervix and vagina: I. Cytologic patterns. Acta Cytol., Chicago, v. 20, n. 6, p. 505-509, 1976.
19. MILLER, S.A. et al. A simple salting out procedure for extraction DNA from human nucleated cells. Nucl. Acid Res., Oxford, v. 16, n. 3, p.1215, 1988.
20. MOSS, S.F.; BLASER, M.J. Mechanisms of disease: Inflammation and the origins of cancer. Nat. Clin. Pract. Oncol., London, v. 2, n. 2, p. 90-97, 2005.
21. MUÑOZ, N. Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol., Amsterdan, v. 19, n. 1-2, p. 1-5, 2000.
22. NANKI, T.; LIPSKY, P.E. Stimulation of T-cell activation by CXCL12/SDF-1 involves a G-protein mediated signaling pathway. Cell. Immunol., New York, v. 214, n. 2, p. 145-154, 2001.
23. O'BRIEN, P.M. et al. Immunoglobulin genes expressed by B-lyphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection. Cancer Immunol. Immunother., Heidelberg, v. 50, n. 10, p. 523-532, 2001.
24. OHTA, M. et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int. J. Cancer, New York, v. 102, n. 3, p. 220-224, 2002.
25. OLIVEIRA, K.B. et al. Analysis of the CC chemokine receptor 5 delta32 polymorphism in a Brazilian population with cutaneous leishmaniasis. J. Cutan. Pathol., Copenhagen, v. 34, n. 1, p. 27-32, 2007.
26. PANZER, U. et al. The chemokines receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int., Malden, v. 67, n. 1, p. 75-81, 2005.
27. PARKIN, D.M.; BRAY, F. Chapter 2: the burden of HPV-related cancers. Vaccine, Kidlinton, v. 24, suppl. 3, p. S11-25, 2006.
28. PARKIN, D.M. et al. Global cancer statistics, 2002. CA Cancer J. Clin., New York, v. 55, n. 2, p. 74-108, 2005.
29. ROSSI, D.; ZLOTNIK, A. The Biology of chemokines and their receptors. Annu. Rev. Immunol., Palo Alto, v. 18, p. 217-242, 2000.
30. SCHIFFMAN, M.; KJAER, S.K. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monographs., Bethesda, n. 31, p. 14-19, 2003.
31. SCHIFFMAN, M. et al. Human papillomavirus and cervical cancer. Lancet, Oxford, v. 370, n. 9590, p. 890-907, 2007.
32. SIDOTI, A. et al. Distribution of the mutated delta32 allele of the ccr5 gene in a sicilian population. Int. J. Immunogenet., Oxford, v. 32, n. 3, p. 193-198, 2005.
33. SINGH, H. et al. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol. Res., New York, v. 17, n. 2, p. 87-91, 2008.
34. SMITH, M.W. et al. Contrasting influence of CCR2 and CCR5 variants on HIV infection and disease progression. Science, Washington, D.C., v. 277, n. 5328, p. 959-965, 1997.
35. SPAGNOLO, P. et al. C-C chemokines receptor 5 gene variants in relation to lung disease in sarcoidosis. Am. J. Respir. Crit. Care Med., New York, v. 2, n. 6, p. 721-728, 2005.
36. SRIVASTAVA, A. et al. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility Scand. J. Immunol., Oxford, v. 67, n. 5, p. 516-522, 2008.
37. VADAY, G.G. et al. Expression of CCL5 (Rantes) and CCR5 in prostate cancer. Prostate, New York, v. 66, n. 2, p. 124-134, 2006.
38. WALBOOMERS, J.M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., Sussex, v. 189, n. 1189, p. 12-19, 1999.
39. YAMAMOTO, L.S.U. et al. A morphological protocol and guide-list on uterine cervix cytology associated to papillomavirus infection. Rev. Inst. Med. Trop. S. Paulo, São Paulo, v. 46, n. 4, p. 189-193, 2004.
40. YANG, X. et al. Analysis of the CC chemokine receptor (CCR5) Delta32 polymorphism in Behcet's disease. Eur. J. Immunogenet., Oxford, v. 31, n. 1, p. 11-14, 2004.
41. ZHENG, B. et al.. Genetic polymorphism of chemokines receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res., Athens, v. 26, n. 5B, p. 3669-3674, 2006.
42. ZÚÑIGA, J.A. et al. Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans. Clin. Exp. Rheumatol., Pisa, v. 21, n. 3, p. 351-352, 2003.